Tag Archive for: drug repurposing
Overcoming Resistance in Metastatic Prostate Cancer: Repurposing Pimitespib
/0 Comments/in Drug repurposing, Preclinical Research/by MaxPredictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/0 Comments/in Drug repurposing, Preclinical Research/by MaxAI-Powered Drug Repurposing Advances: Using Artificial Intelligence to Find New Cancer Treatments
/0 Comments/in Artificial Intelligence/by MaxRepurposing Non-Cancer Drugs: A New Frontier in Personalized Oncology
/0 Comments/in Artificial Intelligence, Preclinical Research/by MaxRepurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/0 Comments/in Drug repurposing, Preclinical Research/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025